Harnessing NLRX1: a new frontier in mitigating inflammation in pulmonary hypertension
NLRX1 may suppress hypoxia-induced lung inflammation and alleviate hypoxia-induced pulmonary hypertension through its anti-inflammatory and antioxidant properties. Therefore, targeted up-regulation of NLRX1 may offer a new strategy for the treatment of HPH.
Authors
- Ying Luo (ORCID: https://orcid.org/0000-0001-5873-8794)
- Zhigui Cai
- Mingxin Bai (ORCID: https://orcid.org/0000-0002-7031-3526)
- Xingan Wu (ORCID: https://orcid.org/0000-0002-2290-0689)
- Rongrong Liu (ORCID: https://orcid.org/0000-0003-2722-578X)
- Yingchou Xiao
- Wenlan Wang (ORCID: https://orcid.org/0000-0003-2764-5557)
Institutions
- Xijing Hospital (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Respiratory Research
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1186/s12931-025-03364-w
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Yakult Bio-Science Foundation
- Shanxi Provincial Key Research and Development Project